Skip to main content
SpringerLink
Log in

Hepatic Encephalopathy

  • Chapter
  • First Online:
Handbook on the Neuropsychology of Aging and Dementia

Part of the book series: Clinical Handbooks in Neuropsychology ((CHNEURO))

Abstract

Hepatic encephalopathy (HE) is a metabolically induced neuropsychiatric syndrome that is not always reversible that can result in significant morbidity and mortality. The incidence is unknown, but it is estimated that most individuals with cirrhosis develop some degree of HE, and advanced age is a risk factor. Cognitive, behavioral, and motor dysfunction are the characteristic features of HE, although the pattern and severity differ among grades. Neuropsychologists are most likely to encounter HE in the context of liver transplant evaluations. The current chapter reviews the classification and pathogenesis of HE and diagnosis and treatment considerations and also provides clinical cases as examples and reviews practical issues that will arise for neuropsychologists involved in the care of patients with HE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Leevy CB, Phillips JA. Hospitalizations during the use of Rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737–41.

    Article  Google Scholar 

  2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25:3–9.

    Article  Google Scholar 

  3. Stewart CA, et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007;13(10):1366–71.

    Article  Google Scholar 

  4. Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.

    Article  Google Scholar 

  5. Bernuau J, Durand F. Early prediction of encephalopathy in hospitalized patients with severe acute liver disease: the narrow window of opportunity for transplant-free survival. J Hepatol. 2009;51(6):977–80.

    Article  Google Scholar 

  6. Bernal W, et al. Acute liver failure. Lancet. 2010;376(9736):190–201.

    Article  Google Scholar 

  7. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the liver. Hepatology. 2014;60(2):715–35.

    Article  Google Scholar 

  8. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23(5):398–406.

    Article  Google Scholar 

  9. Conn HO, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72(4 Pt 1):573–83.

    Article  Google Scholar 

  10. Citro V, et al. Mental status impairment in patients with west haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol. 2007;42(1):79–82.

    Article  Google Scholar 

  11. Dhiman RK, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for study of the liver. J Gastroenterol Hepatol. 2010;25(6):1029–41.

    Article  Google Scholar 

  12. Ferenci P. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–21.

    Article  Google Scholar 

  13. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci. 2003;48(8):1622–6.

    Article  Google Scholar 

  14. Bajaj JS, et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102(9):1903–9.

    Article  Google Scholar 

  15. Bajaj JS, et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology. 2008;47(2):596–604.

    Article  Google Scholar 

  16. Groeneweg M, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45–9.

    Article  Google Scholar 

  17. Prasad S, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45(3):549–59.

    Article  Google Scholar 

  18. Schomerus H, et al. Latent portasystemic encephalopathy. Dig Dis Sci. 1981;26(7):622–30.

    Article  Google Scholar 

  19. Watanabe A, et al. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis. 1995;10(3):239–48.

    Article  Google Scholar 

  20. Wein C, et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39(3):739–45.

    Article  Google Scholar 

  21. Montgomery JY, Bajaj JS. Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep. 2011;13(1):26–33.

    Article  Google Scholar 

  22. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):2014–21.

    Article  Google Scholar 

  23. Strauss E, da Costa MF. The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. Hepato-Gastroenterology. 1998;45(21):900–4.

    Google Scholar 

  24. Marchesini G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

    Article  Google Scholar 

  25. Scaglione S, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690–6.

    Article  Google Scholar 

  26. D’Amico G, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31(5):468–75.

    Article  Google Scholar 

  27. Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.

    Article  Google Scholar 

  28. Benvegnu L, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744–9.

    Article  Google Scholar 

  29. Gentilini P, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92(1):66–72.

    Google Scholar 

  30. Hartmann IJ, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95(8):2029–34.

    Article  Google Scholar 

  31. Watson H, et al. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis. 2013;28(2):301–5.

    Article  Google Scholar 

  32. Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107(7):1043–50.

    Article  Google Scholar 

  33. Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transplant. 2016;21(2):120–6.

    Article  Google Scholar 

  34. Bjerring PN, et al. The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema. Metab Brain Dis. 2009;24(1):5–14.

    Google Scholar 

  35. Córdoba J, Mínguez B. Hepatic encephalopathy. Semin Liver Dis. 2008;28(1):070–80.

    Article  Google Scholar 

  36. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci. 2005;62(19–20):2295–304.

    Article  Google Scholar 

  37. Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis. 1998;21(S1):6–20.

    Google Scholar 

  38. Barbaro G, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 1998;28(2):374–8.

    Article  Google Scholar 

  39. Butterworth RF. Thiamine deficiency-related brain dysfunction in chronic liver failure. Metab Brain Dis. 2009;24(1):189–96.

    Article  Google Scholar 

  40. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57(8):1156–65.

    Article  Google Scholar 

  41. Seyan AS. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16(27):3347–57.

    Article  Google Scholar 

  42. Kosenko E, et al. Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. Brain Res. 2003;981(1–2):193–200.

    Article  Google Scholar 

  43. Master S, Gottstein J, Blei AT. Cerebral blood flow and the development of ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology. 1999;30(4):876–80.

    Article  Google Scholar 

  44. Norenberg M. Oxidative and nitrosative stress in ammonia neurotoxicity. Hepatology. 2003;37(2):245–8.

    Article  Google Scholar 

  45. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44(4):788–94.

    Article  Google Scholar 

  46. Bjerring PN, et al. Cerebral glutamine concentration and lactate–pyruvate ratio in patients with acute liver failure. Neurocrit Care. 2008;9(1):3–7.

    Article  Google Scholar 

  47. Rama Rao KV, et al. Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem Int. 2005;47(1-2):31–8.

    Google Scholar 

  48. Butterworth RF. Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol. 2000;13(6):721–7.

    Article  Google Scholar 

  49. Lozeva V, et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol. 2004;40(5):742–8.

    Article  Google Scholar 

  50. Lozeva-Thomas V. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis. 2004;19(3-4):413–20.

    Article  Google Scholar 

  51. Pidoplichko VI, Dani JA. Acid-sensitive ionic channels in midbrain dopamine neurons are sensitive to ammonium, which may contribute to hyperammonemia damage. Proc Natl Acad Sci. 2006;103(30):11376–80.

    Article  Google Scholar 

  52. Ahboucha S, Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis. 2004;19(3-4):331–43.

    Article  Google Scholar 

  53. Albrecht J, Bender AS, MD N. Potassium-stimulated GABA release is a chloride-dependent but sodium- and calcium-independent process in cultured astrocytes. Acta Neurobiol Exp (Wars). 1998;58(3):169–75.

    Google Scholar 

  54. Odeh M. Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-? Theory. Eur J Clin Investig. 2007;37(4):291–304.

    Article  Google Scholar 

  55. Rolando N. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32(4 Pt 1):734–9.

    Google Scholar 

  56. Vaquero J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125(3):755–64.

    Article  Google Scholar 

  57. Haussinger D, Schliess F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. Neurochem Int. 2005;47(1–2):64–70.

    Article  Google Scholar 

  58. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (5th ed.) Arlington, Virginia: American Psychiatric Association; 2013.

    Google Scholar 

  59. Munoz SJ. Hepatic encephalopathy. Med Clin N Am. 2008;92(4):795–812.

    Article  Google Scholar 

  60. Wehbe E, et al. Reversible hepatic decerebration: a case report and review of the literature. Eur J Gastroenterol Hepatol. 2010;22(6):759–60.

    Google Scholar 

  61. Mukherjee KK, Chhabra R, Khosla VK. Raised intracranial pressure in hepatic encephalopathy. Indian J Gastroenterol. 2003;22(S2):62–5.

    Google Scholar 

  62. Hassanein T, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol. 2009;104(6):1392–400.

    Article  Google Scholar 

  63. Bajaj JS, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138(7):2332–40.

    Article  Google Scholar 

  64. Hassanein TI, Hilsabeck RC, Perry W. Introduction to the hepatic encephalopathy scoring algorithm (HESA). Dig Dis Sci. 2008;53(2):529–38.

    Article  Google Scholar 

  65. Jover R, et al. Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. Am J Gastroenterol. 2003;98(7):1599–604.

    Article  Google Scholar 

  66. McCrea M, et al. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol. 1996;53(8):758–63.

    Article  Google Scholar 

  67. Mooney S, et al. Utility of the repeatable battery for the assessment of neuropsychological status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Arch Clin Neuropsychol. 2007;22(2):175–86.

    Article  Google Scholar 

  68. Weissenborn K, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34(5):768–73.

    Article  Google Scholar 

  69. Ortiz M, et al. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006;44(1):104–10.

    Article  Google Scholar 

  70. Weissenborn K, et al. Memory function in early hepatic encephalopathy. J Hepatol. 2003;39(3):320–5.

    Article  Google Scholar 

  71. Cadranel J-F, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001;96(2):515–8.

    Article  Google Scholar 

  72. Morgan MY, et al. The treatment of hepatic encephalopathy. Metab Brain Dis. 2007;22(3–4):389–405.

    Article  Google Scholar 

  73. Phongsamran PV, et al. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131–48.

    Article  Google Scholar 

  74. Als-Nielsen B. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004; https://doi.org/10.1136/bmj.38048.506134.EE. (published 30 March 2004).

    Article  Google Scholar 

  75. Sharma P, Sharma BC. Management of overt hepatic encephalopathy. J Clin Exp Hepatol. 2015;5(Suppl 1):S82–7.

    Article  Google Scholar 

  76. Sharma P, et al. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47(1):67–73.

    Article  Google Scholar 

  77. Mullen KD, Amodio P, Morgan MY. Therapeutic studies in hepatic encephalopathy. Metab Brain Dis. 2007;22(3–4):407–23.

    Article  Google Scholar 

  78. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13(12):2048–61.

    Article  Google Scholar 

  79. Sharma BC, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63.

    Article  Google Scholar 

  80. Sharma P, Sharma BC. Management patterns of hepatic encephalopathy: a Nationwide survey in India. J Clin Exp Hepatol. 2015;5(3):199–203.

    Article  Google Scholar 

  81. Kircheis G, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25(6):1351–60.

    Article  Google Scholar 

  82. Kondrup J, Müller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol. 1997;27(1):239–47.

    Article  Google Scholar 

  83. Merli M, Riggio O. Dietary and nutritional indications in hepatic encephalopathy. Metab Brain Dis. 2009;24(1):211–21.

    Article  Google Scholar 

  84. Montano-Loza AJ, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–73, 173 e1.

    Article  Google Scholar 

  85. Amodio P, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58(1):325–36.

    Article  Google Scholar 

  86. Ahluwalia V, et al. Impaired gut-liver-brain Axis in patients with cirrhosis. Sci Rep. 2016;6:26800.

    Article  Google Scholar 

  87. Agrawal NK, Sharma B. Prevalence of osteoporosis in otherwise healthy Indian males aged 50 years and above. Arch Osteoporos. 2013;8:116.

    Article  Google Scholar 

  88. McGee RG, et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;9(11):CD008716.

    Google Scholar 

  89. Flamm SL. Hot topics in primary care: diagnosis of cirrhosis and evaluation of hepatic encephalopathy: common errors and their significance for the PCP. J Fam Pract. 2017;66(4 Suppl):S34–9.

    Google Scholar 

  90. Egberts EH, et al. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. Gastroenterology. 1985;88(4):887–95.

    Article  Google Scholar 

  91. Plauth M, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. J Hepatol. 1993;17(3):308–14.

    Article  Google Scholar 

  92. Marchesini G, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. J Hepatol. 1990;11(1):92–101.

    Article  Google Scholar 

  93. Schulz GJ, Campos ACL, JCU C. The role of nutrition in hepatic encephalopathy. Curr Opin Clin Nutr Metab Care. 2008;11:275–80.

    Article  Google Scholar 

  94. Gluud LL, et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143(8):1263–8.

    Article  Google Scholar 

  95. Gluud LL, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013;28(2):221–5.

    Article  Google Scholar 

  96. Stadlbauer V, Wright GAK, Jalan R. Role of artificial liver support in hepatic encephalopathy. Metab Brain Dis. 2009;24(1):15–26.

    Article  Google Scholar 

  97. Stange J. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl. 2000;6(5):603–13.

    Article  Google Scholar 

  98. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537–47.

    Article  Google Scholar 

  99. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. Lancet. 1974;2(7872):81–4.

    Article  Google Scholar 

  100. Ortiz M, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther. 2007;26(6):859–67.

    Article  Google Scholar 

  101. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(S1):23–31.

    Article  Google Scholar 

  102. Sotil EU, et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl. 2009;15(2):184–92.

    Article  Google Scholar 

  103. Eroglu Y, Byrne WJ. Hepatic encephalopathy. Emerg Med Clin North Am. 2009;27(3):401–14.

    Article  Google Scholar 

  104. Mullen KD. Review of the final report of the 1998 working party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(S1):11–6.

    Google Scholar 

  105. Jalan R. Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure. Neurochem Int. 2005;47(1–2):78–83.

    Article  Google Scholar 

  106. Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. Am J Neuroradiol. 2008;29(9):1612–21.

    Article  Google Scholar 

  107. Córdoba J, et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol. 2001;35(5):598–604.

    Article  Google Scholar 

  108. Rovira A, et al. Normalization of T2 signal abnormalities in hemispheric white matter with liver transplant. Neurology. 2002;59(3):335–41.

    Article  Google Scholar 

  109. Córdoba J, et al. T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology. 2003;38(4):1026–33.

    Article  Google Scholar 

  110. Qi R, et al. Altered effective connectivity network of the basal ganglia in low-grade hepatic encephalopathy: a resting-state fMRI study with granger causality analysis. PLoS One. 2013;8(1):e53677.

    Article  Google Scholar 

  111. Foley JM, Watson CW, RD A. Significance of the electroencephalographic changes in hepatic coma. Trans Am Neurol Assoc. 1950;51:161–5.

    Google Scholar 

  112. Guerit J-M, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29(6):789–96.

    Article  Google Scholar 

  113. Guérit JM, et al. Consensus on the use of neurophysiological tests in the intensive care unit (ICU): electroencephalogram (EEG), evoked potentials (EP), and electroneuromyography (ENMG). Neurophysiol Clin/Clin Neurophysiol. 2009;39(2):71–83.

    Article  Google Scholar 

  114. Amodio P, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol. 1999;110(8):1334–44.

    Article  Google Scholar 

  115. Saxena N, et al. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver. 2002;22(3):190–7.

    Google Scholar 

  116. Kügler CFA, et al. Visual event-related P300 potentials in early portosystemic encephalopathy. Gastroenterology. 1992;103(1):302–10.

    Article  Google Scholar 

  117. Kügler CFA, et al. Dynamics of cognitive brain dysfunction in patients with cirrhotic liver disease: an event-related P300 potential perspective. Electroencephalogr Clin Neurophysiol. 1994;91(1):33–41.

    Article  Google Scholar 

  118. Saxena N, et al. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol. 2001;16(3):322–7.

    Article  Google Scholar 

  119. Weissenborn K, et al. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol. 1990;75(4):289–95.

    Article  Google Scholar 

  120. Amodio P, et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004;19(3-4):253–67.

    Google Scholar 

  121. Kircheis G. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35(2):357–66.

    Article  Google Scholar 

  122. Romero-Gómez M, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45(4):879–85.

    Article  Google Scholar 

  123. Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2013;37(5):527–36.

    Article  Google Scholar 

  124. O’Carroll RE. Neuropsychological aspects of liver disease and its treatment. Neurochem Res. 2008;33(4):683–90.

    Google Scholar 

  125. Colombato L. The role of Transjugular intrahepatic portosystemic shunt (TIPS) in the Management of Portal Hypertension. J Clin Gastroenterol. 2007;41(Supplement 3):S344–51.

    Article  Google Scholar 

  126. Montagnese S, et al. Hepatic encephalopathy: you should only comment on what you have actually measured. J Gastroenterol. 2010;45(3):342–3.

    Article  Google Scholar 

  127. Bajaj JS, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50(4):1175–83.

    Article  Google Scholar 

  128. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001;16(1-2):37–41.

    Google Scholar 

  129. Randolph C. Repeatable battery for the assessment of neuropsychological status. San Antonio: The Psychological Corporation; 1998.

    Google Scholar 

  130. Sorrell JH, et al. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci. 2006;60(2):174–81.

    Article  Google Scholar 

  131. Butcher JN, et al. Minnesota multiphasic personality inventory-2. Minnepolis: University of Minnesota Press; 2001.

    Google Scholar 

  132. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Google Scholar 

  133. Younossi ZM, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300.

    Article  Google Scholar 

  134. Ray Kim W. Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with Cholestatic liver disease. Hepatology. 2000;32(5):924–9.

    Article  Google Scholar 

  135. Gralnek IM, et al. Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gastroenterol. 2000;95(12):3552–65.

    Article  Google Scholar 

  136. Zhou Y-q, et al. Development and evaluation of the quality of life instrument in chronic liver disease patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol. 2009;24(3):408–15.

    Article  Google Scholar 

  137. Wechsler D. Wechsler Test of Adult Reading. San Antonio: The Psychological Corporation; 2001.

    Google Scholar 

  138. Hartlage L. The Halstead-Reitan neuropsychology test battery: theory and clinical interpretation second edition by Ralph M. Reitan, PhD & Deborah Wolfson, PhD, Tucson, Az: Neuropsychology Press, 1993. Arch Clin Neuropsychol. 1994;9(3):289–90.

    Article  Google Scholar 

  139. Golden C, Freshwater SM. Stroop Color and Word Test: Revised examiner’s manual. Wood Dale: Stoelting Co.; 2002.

    Google Scholar 

  140. Kaplan E, Goodglass H, Weintraub S. Boston naming test. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

    Google Scholar 

  141. Benton AL. Development of a multilingual aphasia battery. J Neurol Sci. 1969;9(1):39–48.

    Article  Google Scholar 

  142. Kongs SK, et al. Wisconsin Card Sorting Test - 64-Card Version. Odessa: Psychological Assessment Resources; 2000.

    Google Scholar 

  143. Matthews CG, Klove H. Instruction manual for the adult neuropsychology test battery. Madison: University of Wisconsin Medical School; 1964.

    Google Scholar 

  144. Beck AT, Steer RA, Brown G. Beck depression inventory. 2nd ed. San Antonio: The Psychological Corporation; 1996.

    Google Scholar 

  145. Beck AT, et al. Beck anxiety inventory. San Antonio: The Psychological Corporation; 1988.

    Google Scholar 

  146. Amodio P, et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the psychometric hepatic encephalopathy score. A neuropsychological and quantified EEG study. J Hepatol. 2008;49(3):346–53.

    Article  Google Scholar 

  147. Randolph C, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29(5):629–35.

    Article  Google Scholar 

  148. Bajaj JS. Current and future diagnosis of hepatic encephalopathy. Metab Brain Dis. 2010;25(1):107–10.

    Article  Google Scholar 

  149. Amodio P, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010;139(2):510–518.e1-2.

    Article  Google Scholar 

  150. Bajaj JS, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135(5):1591–1600.e1.

    Article  Google Scholar 

  151. Franklin GM, et al. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology. 1988;38(12):1826–9.

    Article  Google Scholar 

  152. Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1973.

    Google Scholar 

  153. Mattarozzi K, et al. Distinguishing between clinical and minimal hepatic encephalopathy on the basis of specific cognitive impairment. Metab Brain Dis. 2005;20(3):243–9.

    Article  Google Scholar 

  154. Ripamonti R, et al. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. Semin Intervent Radiol. 2006;23(2):165–76.

    Article  Google Scholar 

  155. Oscar-Berman M, et al. Profiles of impaired, spared, and recovered neuropsychologic processes in alcoholism. Handb Clin Neurol. 2014;125:183–210.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fort Wayne Medical Education Program, Fort Wayne, IN, USA

    Heidi Musgrave

  2. Neuropsychological Consultants Inc., Fort Wayne, IN, USA

    Heidi Musgrave

  3. Department of Neurology, Dell Medical School, University of Texas - Austin, Austin, TX, USA

    Robin C. Hilsabeck

Authors
  1. Heidi Musgrave
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin C. Hilsabeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin C. Hilsabeck .

Editor information

Editors and Affiliations

  1. Department of Neurology, Weill Cornell Medicine, New York, NY, USA

    Lisa D. Ravdin

  2. Department of Neurology, University of Miami, Miami, FL, USA

    Heather L. Katzen

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Musgrave, H., Hilsabeck, R.C. (2019). Hepatic Encephalopathy. In: Ravdin, L.D., Katzen, H.L. (eds) Handbook on the Neuropsychology of Aging and Dementia. Clinical Handbooks in Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-93497-6_41

Download citation

Publish with us

Policies and ethics

Search

Navigation